CARDIOVASCULAR OUTCOMES FOLLOWING BORTEZOMIB REINITIATION AFTER CONGESTIVE HEART FAILURE DIAGNOSIS IN MULTIPLE MYELOMA
2020
The incidence of congestive heart failure (CHF) in multiple myeloma (MM) patients treated with proteasome inhibitor therapy is reported at 2% - 5%. However, the data are limited regarding safety of resuming proteasome inhibitor therapy after a diagnosis of CHF. A retrospective chart review was
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
1
Citations
NaN
KQI